REFERENCES
- Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta. 1996;1299:125–40.
- Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 445-(4-methylpheny1)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40:1347–65.
- Yoshino T, Kimoto A, Kobayashi S, Noguchi M, Fukunaga M, Hayashi A, et al. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor. Arzneimittelforschung. 2005;55: 394–402.
- Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lan-cet. 1999;354:2106–11.
- Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE. SUCCESS-I Investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006;119:255–66.
- Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized con-trolled trial. JAMA. 1999;282:1921–8.
- Sakamoto C, Soen S. Efficacy and safety of the selective cyclo-oxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. Digestion. 2011;83:108–23.
- Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol. 2001; 96:1019–27.
- Hawkey CC, Svoboda P, Fiedorowicz-Fabrycy IF, Nasonov EL, Pikhlak EG, Cousin M, et al. Gastroduodenal safety and tolera-bility of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. J Rheumatol. 2004;31:1804–10.
- Ohta S, Komai 0, Hanakawa H. Comparison of efficacy of cele-coxib, COX-2 selective inhibitor, and etodolac in patients with osteoarthritis (in Japanese). Seikei Saigaigeka. 2009;52: 901–6.
- Tamai K. Part 5 Individual Diseases, 23 Shoulder Joint-Shoulder Joint Diseases, 3 Degenerative disease of shoulder soft tissue, 4 Frozen shoulder (in Japanese). In: Torisu T, Kokubun S, Nakamura T, Matsuno T, Uchida A, editors. Hyojunseikeigekagaku. 9th ed. Tokyo: Igakushoin; 2005.
- Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347:2104–10.
- Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Aisenberg J, Bhadra P, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther. 2007;25:1211–22.
- Kusunoki N, Yamazaki R, Kawai S. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum. 2002;46(12): 3159–67.
- Kusunoki N, Ito T, Sakurai N, Suguro T, Handa H, Kawai S. A novel celecoxib derivative potently induces apoptosis of human synovial fibroblasts. J Pharmacol Exp Ther. 2005;314(2):796–803.
- Takagishi K. Clinical evaluation of celecoxib (YM177) in frozen shoulder-an open-label uncontrolled study in patients with frozen shoulder (treated with 100 mg bid or 200 mg bid) (in Japanese). Prog Med. 2009;29\(Suppl. 2):2893–917.
- Mastbergen SC, Bijlsma JW, Lafeber FP. Selective COX-2 inhibi-tion is favorable to human early and late-stage osteoarthritic carti-lage: a human in vitro study. Osteoarthr Cartil. 2005;13: 519–26.
- de Boer TN, Huisman AM, Polak AA, Niehoff AG, van Rinsum AC, Saris D, et al. The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment. Osteoarthr Cartil. 2009;17:482–8.